1248 Management LLC Sells 493 Shares of Eli Lilly and Company $LLY

Key Points

• 1248 Management LLC has reduced its stake in Eli Lilly and Company by 25.3%, holding 1,458 shares valued at approximately $1.2 million.
• Eli Lilly recently reported earnings per share of $6.31, exceeding analysts' expectations and showing revenue growth of 37.6% year-over-year.
• The company declared a quarterly dividend of $1.50 per share, representing a 0.8% dividend yield, with the ex-dividend date set for August 15th.

1248 Management LLC reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 25.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,458 shares of the company's stock after selling 493 shares during the quarter. Eli Lilly and Company makes up 0.7% of 1248 Management LLC's investment portfolio, making the stock its 25th largest position. 1248 Management LLC's holdings in Eli Lilly and Company were worth $1,204,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of LLY. WestEnd Advisors LLC boosted its position in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after acquiring an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC bought a new stake in Eli Lilly and Company during the first quarter valued at $27,000. Citizens National Bank Trust Department increased its stake in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new position in shares of Eli Lilly and Company during the first quarter valued at $40,000. Finally, Mascagni Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at $43,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Guggenheim reduced their price objective on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a report on Wednesday, August 13th. HSBC upgraded Eli Lilly and Company from a "reduce" rating to a "hold" rating and boosted their price objective for the stock from $675.00 to $700.00 in a report on Wednesday, August 27th. Cantor Fitzgerald dropped their target price on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a report on Wednesday, August 13th. UBS Group dropped their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Finally, DZ Bank upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus target price of $950.17.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded up $1.08 during midday trading on Wednesday, reaching $736.27. The company's stock had a trading volume of 2,220,178 shares, compared to its average volume of 6,612,480. The business's fifty day simple moving average is $747.03 and its 200-day simple moving average is $783.75. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a market capitalization of $696.85 billion, a P/E ratio of 45.36, a P/E/G ratio of 1.02 and a beta of 0.47. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $954.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the company earned $3.92 earnings per share. The company's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 39.22%.

Insider Activity at Eli Lilly and Company

In related news, Director Jamere Jackson acquired 200 shares of the stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares of the company's stock, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director J Erik Fyrwald bought 1,565 shares of the stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares of the company's stock, valued at $47,903,686.74. This represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 4,514 shares of company stock worth $2,894,841 in the last quarter. 0.14% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.